These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 27527850)

  • 1. PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications.
    Xing W; Dresser K; Zhang R; Evens AM; Yu H; Woda BA; Chen BJ
    Oncotarget; 2016 Sep; 7(37):59976-59986. PubMed ID: 27527850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
    Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
    Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas.
    Liu Y; Ma J; Yu K; Li M; Liu F; Yan Q; Wang Z; Guo S
    Pathol Res Pract; 2018 Apr; 214(4):507-512. PubMed ID: 29598887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of PD-L1 expression in primary gastric and intestinal diffuse large B-cell lymphoma.
    Ishikawa E; Nakamura M; Shimada K; Tanaka T; Satou A; Kohno K; Sakakibara A; Furukawa K; Yamamura T; Miyahara R; Nakamura S; Kato S; Fujishiro M
    J Gastroenterol; 2020 Jan; 55(1):39-50. PubMed ID: 31493237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.
    Ishikawa E; Kato S; Shimada K; Tanaka T; Suzuki Y; Satou A; Kohno K; Sakakibara A; Yamamura T; Nakamura M; Miyahara R; Goto H; Nakamura S; Hirooka Y
    Cancer Med; 2018 Dec; 7(12):6051-6063. PubMed ID: 30449068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma.
    Kwon HJ; Yang JM; Lee JO; Lee JS; Paik JH
    J Transl Med; 2018 Nov; 16(1):320. PubMed ID: 30458835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.
    Kwon D; Kim S; Kim PJ; Go H; Nam SJ; Paik JH; Kim YA; Kim TM; Heo DS; Kim CW; Jeon YK
    Histopathology; 2016 Jun; 68(7):1079-89. PubMed ID: 26426431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.
    Kiyasu J; Miyoshi H; Hirata A; Arakawa F; Ichikawa A; Niino D; Sugita Y; Yufu Y; Choi I; Abe Y; Uike N; Nagafuji K; Okamura T; Akashi K; Takayanagi R; Shiratsuchi M; Ohshima K
    Blood; 2015 Nov; 126(19):2193-201. PubMed ID: 26239088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.
    Dong L; Lv H; Li W; Song Z; Li L; Zhou S; Qiu L; Qian Z; Liu X; Feng L; Meng B; Fu K; Wang X; Pan-Hammarström Q; Wang P; Wang X; Zhang H
    Oncotarget; 2016 May; 7(22):33350-62. PubMed ID: 27147575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EBV-positive diffuse large B-cell lymphoma features PD-L1 protein but not mRNA overexpression.
    Xue T; Wang WG; Zhou XY; Li XQ
    Pathology; 2018 Dec; 50(7):725-729. PubMed ID: 30389217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
    Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
    Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent expression of PD-L1 in BLS-type diffuse large B-cell lymphoma: implications for aggressiveness and immunotherapy.
    Yang CF; Yu YT; Wang SH; Chen YP; Chen TY; Hsu CY; Medeiros LJ; Chang KC
    Pathology; 2024 Apr; 56(3):367-373. PubMed ID: 38290893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological analysis of neoplastic PD-L1-positive EBV
    Takahara T; Satou A; Ishikawa E; Kohno K; Kato S; Suzuki Y; Takahashi E; Ohashi A; Asano N; Tsuzuki T; Nakamura S
    Virchows Arch; 2021 Mar; 478(3):541-552. PubMed ID: 32803453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
    Xie M; Huang X; Ye X; Qian W
    Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas.
    Anastasiadou E; Stroopinsky D; Alimperti S; Jiao AL; Pyzer AR; Cippitelli C; Pepe G; Severa M; Rosenblatt J; Etna MP; Rieger S; Kempkes B; Coccia EM; Sui SJH; Chen CS; Uccini S; Avigan D; Faggioni A; Trivedi P; Slack FJ
    Leukemia; 2019 Jan; 33(1):132-147. PubMed ID: 29946193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
    Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
    Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of PD-L1 detection assays and corresponding significance in evaluation of diffuse large B-cell lymphoma.
    Huang S; Nong L; Liang L; Zheng Y; Wang W; Liu J; Li D; Li X; Wang Y; Zhang B; Li T
    Cancer Med; 2019 Jul; 8(8):3831-3845. PubMed ID: 31150165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.
    Furuse M; Kuwabara H; Ikeda N; Hattori Y; Ichikawa T; Kagawa N; Kikuta K; Tamai S; Nakada M; Wakabayashi T; Wanibuchi M; Kuroiwa T; Hirose Y; Miyatake SI
    BMC Cancer; 2020 Apr; 20(1):277. PubMed ID: 32248797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.
    Xu-Monette ZY; Li J; Xia Y; Crossley B; Bremel RD; Miao Y; Xiao M; Snyder T; Manyam GC; Tan X; Zhang H; Visco C; Tzankov A; Dybkaer K; Bhagat G; Tam W; You H; Hsi ED; van Krieken JH; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; Winter JN; Medeiros JT; Xu B; Li Y; Kirsch I; Young KH
    J Immunother Cancer; 2019 Oct; 7(1):272. PubMed ID: 31640780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.